Advertisement
Canada markets closed

  • S&P/TSX

    21,947.41
    +124.21 (+0.57%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +449.98 (+1.18%)
     

  • CAD/USD

    0.7308
    -0.0006 (-0.08%)
     

  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     

  • Bitcoin CAD

    87,488.20
    +399.49 (+0.46%)
     

  • CMC Crypto 200

    1,330.22
    +53.24 (+4.17%)
     

  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     

  • RUSSELL 2000

    2,035.72
    +19.61 (+0.97%)
     

  • 10-Yr Bond

    4.5000
    -0.0710 (-1.55%)
     

  • NASDAQ

    16,156.33
    +315.33 (+1.99%)
     

  • VOLATILITY

    13.49
    -1.19 (-8.11%)
     

  • FTSE

    8,213.49
    +41.34 (+0.51%)
     

  • NIKKEI 225

    38,236.07
    -38.03 (-0.10%)
     

  • CAD/EUR

    0.6787
    -0.0030 (-0.44%)
     

Xencor to Present at Upcoming Investor Conferences

Business Wire
·1 min read

PASADENA, Calif., February 28, 2024--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at multiple upcoming investor conferences:

  • TD Cowen 44th Annual Health Care Conference
    Date: Wednesday, March 6, 2024
    Presentation Time: 12:50 p.m. ET / 9:50 a.m. PT
    Location: Boston

  • Leerink Partners Global Biopharma Conference
    Date: Tuesday, March 12, 2024
    Presentation Date/Time: Wednesday, March 13, 2024, 9:20 a.m. ET / 6:20 a.m. PT
    Location: Miami

  • Jefferies Biotech on the Bay Summit
    Date: Wednesday, March 13, 2024
    Location: Miami

  • Barclays Global Healthcare Conference
    Date: Thursday, March 14, 2024
    Presentation Time: 11:15 a.m. ET / 8:15 a.m. PT
    Location: Miami

Live webcasts of the Cowen, Leerink and Barclays presentations will be available under "Events & Presentations" in the Investors section of the Company’s website located at www.xencor.com. Replays of the events will be available on the Xencor website for at least 30 days following the presentations.

ADVERTISEMENT

About Xencor

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and other serious diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and three XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240228121602/en/

Contacts

Charles Liles
cliles@xencor.com
(626) 737-8118